Verona Pharma plc (VRNA)
NASDAQ: VRNA · IEX Real-Time Price · USD
15.46
-0.05 (-0.32%)
At close: Jul 2, 2024, 4:00 PM
15.45
-0.01 (-0.06%)
After-hours: Jul 2, 2024, 7:20 PM EDT
Verona Pharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
79
Market Cap
1.17B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 458.00K | -39.54M | -98.86% |
Dec 31, 2021 | 40.00M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AtriCure | 414.60M |
Xencor | 162.18M |
Arcutis Biotherapeutics | 106.39M |
Prothena Corporation | 89.25M |
Immatics | 80.95M |
4D Molecular Therapeutics | 20.45M |
Spyre Therapeutics | 688.00K |
VRNA News
- 5 days ago - First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product - Benzinga
- 5 days ago - Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month - Reuters
- 6 days ago - US FDA approves Verona Pharma's therapy for 'smoker's lungs' - Reuters
- 6 days ago - Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) - GlobeNewsWire
- 8 days ago - 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More - Benzinga
- 7 weeks ago - Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS - GlobeNewsWire
- 2 months ago - Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 - GlobeNewsWire